Indication: 1. This product can be used as an alternative drug for the following diseases: (1) Rickettsial diseases, including epidemic typhus, endemic typhus, Rocky Mountain fever, scrub typhus and Q fever. (2) Mycoplasma infections. (3) Chlamydia infections, including psittacosis, venereal diseases, lymphoma, nonspecific urethritis, salpingitis, cervicitis and trachoma. (4) Relapsing fever. (5) Brucellosis. (6) Cholera. (7) Tularemia. (8) Plague. (9) Chancroid. It should be used in combination with aminoglycosides to treat brucellosis and plague. 2. Due to the serious drug resistance of common pathogens to this product, it can only be used as an alternative drug when the pathogen is sensitive to this product.

Indication: 1. This product can be used as an alternative drug for the following diseases: (1) Rickettsial diseases, including epidemic typhus, endemic typhus, Rocky Mountain fever, scrub typhus and Q fever. (2) Mycoplasma infections. (3) Chlamydia infections, including psittacosis, venereal diseases, lymphoma, nonspecific urethritis, salpingitis, cervicitis and trachoma. (4) Relapsing fever. (5) Brucellosis. (6) Cholera. (7) Tularemia. (8) Plague. (9) Chancroid. It should be used in combination with aminoglycosides to treat brucellosis and plague. 2. Due to the serious drug resistance of common pathogens to this product, it can only be used as an alternative drug when the pathogen is sensitive to this product.

Indication: 1 This product can be used as an optional drug for the following diseases: (1) Rickettsial diseases, including epidemic typhus, endemic typhus, Rocky Mountain fever, scrub typhus and Q fever. (2) Mycoplasma infections. (3) Chlamydia infections, including psittacosis, venereal diseases, lymphoedema, nonspecific urethritis, salpingitis, cervicitis and trachoma. (4) Relapsing fever. (5) Brucellosis. (6) Cholera. (7) Tularemia. (8) Plague. (9) Chancroid. It should be used in combination with aminoglycosides to treat brucellosis and plague. 2 Since common pathogens are currently resistant to this product,

Indication: 1 This product can be used as an optional drug for the following diseases: (1) Rickettsial diseases, including epidemic typhus, endemic typhus, Rocky Mountain fever, scrub typhus and Q fever. (2) Mycoplasma infections. (3) Chlamydia infections, including psittacosis, venereal diseases, lymphoedema, nonspecific urethritis, salpingitis, cervicitis and trachoma. (4) Relapsing fever. (5) Brucellosis. (6) Cholera. (7) Tularemia. (8) Plague. (9) Chancroid. It should be used in combination with aminoglycosides to treat brucellosis and plague. 2 Since common pathogens are currently resistant to this product,

Indication: 1. This product is used as the first choice or optional drug for the following diseases: (1) Rickettsial diseases, including epidemic typhus, endemic typhus, Rocky Mountain fever, scrub typhus and Q fever. (2) Mycoplasma infections. (3) Chlamydia infections, including psittacosis, venereal diseases, lymphoedema, nonspecific urethritis, salpingitis, cervicitis and trachoma. (4) Relapsing fever. (5) Brucellosis. (6) Cholera. (7) Tularemia. (8) Plague. (9) Chancroid. It should be used in combination with aminoglycosides for the treatment of brucellosis and plague. 2. Due to the serious resistance of common pathogens to tetracyclines, this drug is only indicated when the pathogen is sensitive to this drug. Since hemolytic streptococci are mostly resistant to this drug, it is not suitable for infections caused by this type of bacteria.

Indication: 1. This product is used as the first choice or optional drug for the following diseases: (1) Rickettsial diseases, including epidemic typhus, endemic typhus, Rocky Mountain fever, scrub typhus and Q fever. (2) Mycoplasma infections. (3) Chlamydia infections, including psittacosis, venereal diseases, lymphoedema, nonspecific urethritis, salpingitis, cervicitis and trachoma. (4) Relapsing fever. (5) Brucellosis. (6) Cholera. (7) Tularemia. (8) Plague. (9) Chancroid. It should be used in combination with aminoglycosides for the treatment of brucellosis and plague. 2. Due to the serious resistance of common pathogens to tetracyclines, this drug is only indicated when the pathogen is sensitive to this drug. Since hemolytic streptococci are mostly resistant to this drug, it is not suitable for infections caused by this type of bacteria.

Indication: 1. This product is used as the first choice or optional drug for the following diseases: (1) Rickettsial diseases, including epidemic typhus, endemic typhus, Rocky Mountain fever, scrub typhus and Q fever. (2) Mycoplasma infections. (3) Chlamydia infections, including psittacosis, venereal diseases, lymphoedema, nonspecific urethritis, salpingitis, cervicitis and trachoma. (4) Relapsing fever. (5) Brucellosis. (6) Cholera. (7) Tularemia. (8) Plague. (9) Chancroid. It should be used in combination with aminoglycosides for the treatment of brucellosis and plague. 2. Due to the serious resistance of common pathogens to tetracyclines, this drug is only indicated when the pathogen is sensitive to this drug. Since hemolytic streptococci are mostly resistant to this drug, it is not suitable for infections caused by this type of bacteria.

Indication: The main indications of this product are the following infections caused by sensitive strains: 1. Urinary tract infections caused by sensitive strains of Escherichia coli, Klebsiella, Enterobacter, Proteus mirabilis, Proteus vulgaris and Morganella. 2. Acute otitis media in children over 2 years old caused by Streptococcus pneumoniae or Haemophilus influenzae. 3. Acute exacerbation of chronic bronchitis in adults caused by Streptococcus pneumoniae or Haemophilus influenzae. 4. Intestinal infections and Shigella infections caused by sensitive strains of Shigella flexneri or Shigella sonnei. 5. This product is the first choice for the treatment of Pneumocystis carinii pneumonia. 6. For the prevention of Pneumocystis carinii pneumonia, patients with a history of at least one attack of Pneumocystis carinii disease or HIV-infected adults with a CD4 lymphocyte count ≤ 200/mm3 or less than 20% of the total lymphocyte count can be used.